NCT02579616View on ClinicalTrials.gov

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 23, 2015

Primary Completion Date

November 22, 2016

Study Completion Date

February 27, 2019

Conditions
Biliary Tract Cancer
Interventions
DRUG

Lenvatinib

Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.

Trial Locations (7)

Unknown

Nagoya

Kashiwa

Yokohama

Ina-machi

Chuo-ku

Koto-ku

Mitaka

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02579616 - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | Biotech Hunter | Biotech Hunter